TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Medivir AB ( (SE:MVIR) ) has provided an announcement.
Medivir AB has announced a delay in appointing its Nomination Committee for the 2026 Annual General Meeting until after the completion of a planned rights issue. This decision deviates from the Swedish Code of Corporate Governance but is aimed at ensuring the committee reflects the actual ownership structure following potential significant changes in ownership due to the rights issue. The new committee composition is expected to be announced in January 2026.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a pharmaceutical company focused on developing innovative treatments for cancer, particularly in areas with high unmet medical needs. The company emphasizes drug candidates for indications where existing therapies are limited or absent, aiming to provide significant improvements for patients. Medivir’s primary focus is on fostroxacitabine bralpamide (fostrox), a drug candidate targeting liver cancer cells while minimizing side effects. The company operates through collaborations and partnerships, and its shares are listed on Nasdaq Stockholm’s Small Cap list.
Average Trading Volume: 523,170
Technical Sentiment Signal: Sell
Current Market Cap: SEK60.9M
Learn more about MVIR stock on TipRanks’ Stock Analysis page.